NeurAxis (NRXS) said Monday it received a new 510(k) clearance from the US Food and Drug Administration for its IB-Stim nerve stimulator for functional abdominal pain relief, expanding its indication for use in people between 8 and 21 years of age from a previous indication for 11- to 18-year olds.
IB-Stim is a non-surgical device that sends "gentle" electrical impulses into cranial nerve bundles in the ear, the medical technology company said.
Price: 2.26, Change: -0.33, Percent Change: -12.74
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。